BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BC Extra | Jan 22, 2020
Company News

Despite outreach to over 18 companies, Lilly was only biopharma to offer Dermira takeout

Dermira’s multiyear quest to find a partner for lebrikizumab found it knocking on the doors of over 18 biopharmas, but only Eli Lilly was interested in submitting a bid to acquire the autoimmune and dermatology...
BC Extra | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent. The price -- $18.75 per share -- is a premium of...
BC Extra | Dec 11, 2019
Clinical News

Leo’s IL-13 mAb hits in atopic dermatitis; how it stacks up against Dupixent remains a question mark

Over a year after the primary completion of tralokinumab’s Phase III studies, Leo Pharma has said the anti-IL-13 mAb met the primary endpoint in all three trials to treat moderate-to-severe atopic dermatitis without divulging details....
BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BC Extra | Dec 10, 2019
Company News

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

After searching for a new candidate to add to its immuno-dermatology pipeline, Janssen Biotech Inc. will spend $750 up front to acquire bermekimab, a clinical anti-IL-1α antibody, from XBiotech Inc. The mAb is first being...
BC Extra | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

AnaptysBio lost over $700 million in market cap Friday after reporting that IL-33 inhibitor etokimab, which it had hoped would compete with blockbuster inflammatory disease drug Dupixent, missed the primary endpoint in a trial to...
BC Extra | Nov 5, 2019
Clinical News

Regeneron’s Libtayo shows response rate in line with Keytruda’s in first-line NSCLC

Interim data from a Phase III study showed that the response rate to Regeneron’s Libtayo among first-line lung cancer patients was comparable to the rate in the label of competing PD-1 inhibitor Keytruda. If upcoming...
BC Extra | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance  On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BC Extra | Oct 19, 2019
Clinical News

Dermira data could bolster bid as Dupixent alternative

Dermira added $80 million to its market cap Friday on detailed Phase IIb data that lend additional support to the idea that its atopic dermatitis therapy could compete with Dupixent on dosing. Dermira Inc. (NASDAQ:DERM)...
Items per page:
1 - 10 of 111